GW0742 Solution 10mg/ml – 50ml
| Application | Potent PPARβ and PPARδ agonist |
| Concentration | 1% (10mg/ml) |
| Composition | 99% PEG400, 1% GW0742 (>99% purity) |
| CAS | 317318-84-6 |
| Molar Mass | 471.5 g/mol |
| Chemical Formula | C21H17F4NO3S2 |
| Synonyms | GW0742, GW 0742, GW-0742, GW0742X |
| Storage | Minimize open air exposure, store in a cool dry place |
| Terms | For laboratory research use only. Not for human or animal consumption. |
What Is GW0742?
GW0742 is a potent synthetic PPARδ agonist from the same GlaxoSmithKline chemical series that produced GW501516 (Cardarine), but with a higher binding affinity (EC50 ~1 nM vs ~4 nM for GW501516) and greater selectivity for PPARδ over PPARα and PPARγ. This enhanced selectivity makes GW0742 the preferred tool compound for research specifically targeting PPARδ biology without pan-PPAR activity confounding experimental results.
Mechanism and Research Advantages Over GW501516
Like GW501516, GW0742 activates fatty acid catabolism gene programs in skeletal muscle and liver, producing improved metabolic flexibility, reduced triglycerides, and elevated HDL in animal models. However, its greater PPARδ selectivity means researchers can attribute observed effects more precisely to PPARδ-specific signaling — a critical advantage in mechanistic studies where distinguishing PPARδ from PPARα effects matters.
GW0742 has also been studied for its anti-inflammatory effects in gut ischemia/reperfusion injury models, cardiovascular protective effects in pulmonary hypertension models, and neuroprotective effects in Alzheimer’s mouse models — a broader range of preclinical applications than typically reported for GW501516.
Research Applications
- Cardiovascular research: Reduces right ventricular hypertrophy and relaxes pulmonary vessels in pulmonary hypertension models.
- Neuroprotection: Enhances fatty acid oxidation in astrocytes; studied in Alzheimer’s mouse models.
- Metabolic disease: Ameliorates insulin resistance and dyslipidemia in high-fructose diet models.
- Inflammatory conditions: Anti-inflammatory in intestinal ischemia/reperfusion models.
Related Research Compounds
GW0742 is commonly studied alongside GW501516 for direct PPARδ agonist comparisons, and alongside SR9009 and SR9011 for broader metabolic panel studies. In anabolic/metabolic combination designs, Ostarine or RAD-140 are frequently added as the anabolic arm.
Read our comparison: GW0742 vs GW501516: Comparing PPARδ Agonists for Metabolic Research.
For laboratory research use only.
Reviews
There are no reviews yet.